Global Patent Index - EP 1056471 A4

EP 1056471 A4 2001-05-30 - TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS

Title (en)

TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS

Title (de)

BEHANDLUNG ATOPISCHER DERMATITIS MIT IgE ANTAGONISTEN

Title (fr)

TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE

Publication

EP 1056471 A4 (EN)

Application

EP 99901309 A

Priority

  • US 9900135 W
  • US 1526998 A
  • US 7303398 P

Abstract (en)

[origin: WO9938531A1] The invention relates to a pharmaceutical composition for treatment of atopic dermatitis comprising a suitable IgE antagonist which does not induce release of the mediators of allergy; for example, anti-IgE antibodies which bind to secreted IgE, to membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the Fc epsilon RI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to Fc epsilon RII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired. The pharmaceutical composition can be administered systemically or topically.

IPC 1-7 (main, further and additional classification)

A61K 39/395; C07K 16/42

IPC 8 full level (invention and additional information)

C12N 15/02 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61P 17/00 (2006.01); A61P 37/08 (2006.01); C07K 16/42 (2006.01); A61K 38/00 (2006.01)

CPC (invention and additional information)

C07K 16/4291 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01)

Citation (search report)

  • [XD] EP 0589840 A1 19940330 - CIBA GEIGY AG [CH], et al
  • [X] WO 9217207 A1 19921015 - TANOX BIOSYSTEMS INC [US]
  • [X] EP 0648499 A1 19950419 - RA CHISEI [JP], et al
  • [X] EP 0657534 A1 19950614 - GREEN CROSS CORP [JP], et al
  • [PX] WO 9804718 A1 19980205 - CIBA GEIGY AG [CH], et al
  • [XD] CORNE JONATHAN ET AL: "The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics.", 1997, JOURNAL OF CLINICAL INVESTIGATION, VOL. 99, NR. 5, PAGE(S) 879-887, ISSN: 0021-9738, XP002164091
  • [X] HAAK-FRENDSCHO M. ET AL.: "Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo", 1993, JOURNAL OF IMMUNOLOGY, VOL. 151, NR.1, PAGE(S) 351-358, XP000942183
  • [A] GRAHAM BROWN R. A. C. ET AL.: "Therapeutics in atopic dermatitis", 1997, ADVANCES IN DERMATOLOGY, VOL. 13, PAGE(S) 3-31, XP000983988
  • See also references of WO 9938531A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9938531 A1 19990805; AU 2103699 A 19990816; CN 1289253 A 20010328; EP 1056471 A1 20001206; EP 1056471 A4 20010530; JP 2002501905 A 20020122

INPADOC legal status


2005-02-09 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20040810

2002-10-16 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20020829

2001-05-30 [A4] SUPPLEMENTARY SEARCH REPORT

- Effective date: 20010412

2001-05-30 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A4

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2000-12-06 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000828

2000-12-06 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE